23/11/2025 NovelWise's NBM-BMX received the FDA orphan drug designation for uveal melanoma ( Ref ) The US FDA granted the orphan drug designation to NovelWise Pharmaceutical Corporation's NBM-BMX (selective HDAC8 inhibitor) for the treatment of uveal melanoma. John Soong, MD, Chief Executive Officer, NovelWise: “ Receiving both Fast Track Designation and now Orphan Drug Designation underscores NBM-BMX’s promise in addressing a high unmet medical need for patients with uveal m